Altered testimony, allegedly hidden statistics and the enlarged breasts of a boy throughout his high school years were the focus of contentious closing arguments in the ongoing Risperdal trial.
Thomas R. Kline of Kline & Specter, who is representing Timothy Stange in Stange v. Janssen Pharmaceuticals, argued Thursday that Janssen Pharmaceuticals failed to turn over data linking the antipsychotic drug Risperdal to the condition called gynecomastia, which causes excessive growth of breast tissue in males. Kline said the omitted statistics and allegedly inadequate warnings led a pediatric neurologist to prescribe Risperdal to Stange when he was about 12 years old. According to Kline, the drug then caused Stange’s breasts to grow and remain enlarged until he had a double mastectomy when he was 18 in 2012.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
